Exchange: NASDAQ·Updated 07:41 PM EDT
News
all
press releases
SINTX TECHNOLOGIES (SINT) Moves to Buy: Rationale Behind the Upgrade
SINTX TECHNOLOGIES (SINT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks
More News
Globus Medical (GMED) Q2 Earnings and Revenues Surpass Estimates
Globus Medical (GMED) delivered earnings and revenue surprises of +19.64% and +0.35%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
LivaNova (LIVN) Q2 Earnings and Revenues Beat Estimates
LivaNova (LIVN) delivered earnings and revenue surprises of +16.67% and +2.90%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
ClearPoint Neuro, Inc. (CLPT) Reports Q2 Loss, Misses Revenue Estimates
ClearPoint Neuro (CLPT) delivered earnings and revenue surprises of -31.03% and -16.31%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
AxoGen (AXGN) Tops Q2 Earnings and Revenue Estimates
AxoGen (AXGN) delivered earnings and revenue surprises of +33.33% and +4.31%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
PAVmed Inc. (PAVM) Reports Q1 Loss, Lags Revenue Estimates
PAVmed (PAVM) delivered earnings and revenue surprises of -69.57% and -78.00%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Sangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue Estimates
Sangamo (SGMO) delivered earnings and revenue surprises of -100.00% and -84.82%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Rapid Micro Biosystems, Inc. (RPID) Reports Q1 Loss, Tops Revenue Estimates
Rapid Micro Biosystems (RPID) delivered earnings and revenue surprises of -24.00% and +6.69%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Artivion (AORT) Q1 Earnings and Revenues Surpass Estimates
Artivion (AORT) delivered earnings and revenue surprises of +33.33% and +0.33%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Waters (WAT) Beats Q1 Earnings and Revenue Estimates
Waters (WAT) delivered earnings and revenue surprises of +17.11% and +5.20%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks

Advertisement|Remove ads.